Sponsor

MacroGenics

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name MacroGenics appears in 26 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials26
Recruiting shown1
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

26 shown
A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470 · lead sponsor · 2024-03-06
RECRUITING
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerNCT05848011 · lead sponsor · 2023-09-28
COMPLETED
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsNCT05551117 · lead sponsor · 2023-06-13
TERMINATED
A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral TherapyNCT05261191 · lead sponsor · 2022-09-26
COMPLETED
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsNCT05293496 · lead sponsor · 2022-04-19
COMPLETED
MGD019 DART® Protein in Unresectable/Metastatic CancerNCT03761017 · lead sponsor · 2018-12-12
COMPLETED
MGC018 With or Without MGA012 in Advanced Solid TumorsNCT03729596 · lead sponsor · 2018-11-21
TERMINATED
MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral TherapyNCT03570918 · lead sponsor · 2018-09-25
COMPLETED
A Study of MGD013 in Patients With Unresectable or Metastatic NeoplasmsNCT03219268 · lead sponsor · 2017-08-18
COMPLETED
Safety Study of MGD009 in B7-H3-expressing TumorsNCT02628535 · lead sponsor · 2015-09-01
TERMINATED
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerNCT02492711 · lead sponsor · 2015-08-24
COMPLETED
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory CancerNCT02475213 · lead sponsor · 2015-07-01
COMPLETED
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory CancerNCT02381314 · lead sponsor · 2015-03-26
COMPLETED
Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast CancerNCT01828021 · lead sponsor · 2013-03-01
COMPLETED
Safety Study of MGA271 in Refractory CancerNCT01391143 · lead sponsor · 2011-07-01
COMPLETED
Subcutaneous Administration of Teplizumab in Adults With Type 1 DiabetesNCT01189422 · lead sponsor · 2010-08-01
TERMINATED
Safety Study of MGAH22 in HER2-positive CarcinomasNCT01148849 · lead sponsor · 2010-07-01
COMPLETED
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes MellitusNCT00920582 · lead sponsor · 2009-09-01
TERMINATED
Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)NCT00870818 · lead sponsor · 2009-02-01
TERMINATED
The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes MellitusNCT00385697 · lead sponsor · 2006-10-01
COMPLETED
RAV12 in Treating Patients With Metastatic or Recurrent AdenocarcinomaNCT00101972 · lead sponsor · 2004-12-01
COMPLETED
MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung CancerNCT06227546 · collaborator · 2024-04-15
ACTIVE_NOT_RECRUITING
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate CancerNCT06014255 · collaborator · 2024-02-16
ACTIVE_NOT_RECRUITING
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast CancerNCT05227131 · collaborator · 2022-05-15
WITHDRAWN
MARGetuximab Or Trastuzumab (MARGOT)NCT04425018 · collaborator · 2020-07-13
ACTIVE_NOT_RECRUITING
Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate CancerNCT02923180 · collaborator · 2017-02-14
ACTIVE_NOT_RECRUITING

Sponsor roles

lead sponsor21
collaborator5
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.